In diabetes, much attention goes to sugar control, insulin levels, and the threat of nerve damage. But a new study reveals ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

That’s how long it takes, on average, for the pounds to begin creeping back after someone stops taking the world’s most ...